Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma

Fig. 1

Kaplan–Meier curves showing the impact of making clinical decisions based on MRD. a PFS from the first MRD datapoint, comparing patients who underwent a change in therapy based on MRD with those in whom no change in therapy was made. b MRD-negative patients: treatment discontinuation (maintenance or transplant) vs. no change in therapy. c MRD-positive patients: beginning a new therapy or intensifying therapy vs. no change in therapy

Back to article page